-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
-
How to Turn Your Garage into Usable Living Space
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 17
-
PRAAMS AI Co-Investor Now Covers 400,000+ Global Instruments, With Responses From 3 Seconds, Cost From US$0.01, and Scalability to Millions of Users
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
FDA recognition marks a significant regulatory milestone for MedMira's innovative, instrument-free point-of-care diagnostic technology.
HALIFAX, NS / ACCESS Newswire / November 17, 2026 / MedMira Inc. (TSXV:MIR), a developer and manufacturer of rapid diagnostic technologies, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Multiplo® Complete Syphilis (TP/nTP) Antibody Test.
The designation, granted through the FDA's Center for Devices and Radiological Health (CDRH), recognizes the device's potential to provide a more effective diagnostic approach for syphilis, a serious infectious disease that continues to present significant public health challenges in the United States and worldwide.
The Multiplo® Complete Syphilis (TP/nTP) Antibody Test utilizes MedMira's proprietary Rapid Vertical Flow (RVF®) Technology to simultaneously detect treponemal (TP) and non-treponemal (nTP) antibodies from a single fingerstick whole blood specimen. Unlike conventional laboratory-based testing approaches that may require separate testing procedures, the device provides both antibody results in a rapid, visually interpreted format without the need for specialized instrumentation.
A Significant Milestone for MedMira
"This is an extraordinary milestone for MedMira and a tremendous recognition of the dedication, perseverance, and scientific innovation of our entire team," said Hermes Chan, Chief Executive Officer of MedMira Inc. "The FDA's decision reinforces the potential significance of our technology and represents an important step as we advance our development program toward the U.S. market."
"We are also particularly encouraged that, following the Breakthrough Device Designation, FDA's Total Product Life Cycle Advisory Program (TAP) team has invited MedMira to apply for enrollment in its TAP Pilot. We welcome this opportunity to pursue closer collaboration with FDA as we advance our U.S. clinical and regulatory development strategy."
"For many years, we have believed that meaningful innovation in diagnostics should not only advance scientific capabilities but also make essential healthcare more accessible to the people who need it most. For me, this achievement represents much more than a regulatory milestone. It reflects our longstanding belief that the real purpose of innovation is using science to improve people's lives."
Addressing an Important Public Health Need
Syphilis continues to pose significant challenges to healthcare systems, with delayed diagnosis and treatment contributing to ongoing transmission and potentially serious complications, including congenital syphilis.
Conventional syphilis diagnosis typically relies on both treponemal and non-treponemal testing, which may require laboratory infrastructure, multiple procedures, and additional patient follow-up.
MedMira's Multiplo® Complete Syphilis (TP/nTP) Antibody Test is designed to combine these two complementary antibody measurements into a single point-of-care procedure, potentially enabling healthcare professionals to obtain clinically relevant information more quickly.
The technology may be particularly valuable in community health centres, outreach programs, remote communities, and other healthcare settings where immediate access to conventional laboratory services is limited.
FDA Breakthrough Devices Program
The FDA's Breakthrough Devices Program is intended to facilitate the development and review of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
Devices granted Breakthrough Device Designation may benefit from prioritized interaction with the FDA and opportunities for more frequent communication regarding development plans, clinical study design, and regulatory requirements.
The designation does not constitute FDA clearance or approval for commercial marketing in the United States, nor does it eliminate applicable regulatory requirements.
About MedMira MedMira is a leading developer and manufacturer of Rapid Vertical Flow® diagnostics. The Company's tests provide hospitals, labs, clinics, and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company's tests are sold globally under the REVEAL®, REVEALCOVID-19®, Multiplo® and Miriad® brands. Based on its patented Rapid Vertical Flow® Technology, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
MedMira Contact:
Markus Meile
Chief Financial Officer
MedMira Inc.
[email protected]
Phone 902-450-1588
SOURCE: MedMira, Inc.
View the original press release on ACCESS Newswire
N.Walker--AT